Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome - PubMed (original) (raw)
Comparative Study
. 2006 Dec;45(12):1130-42.
doi: 10.1002/gcc.20376.
Affiliations
- PMID: 16958102
- DOI: 10.1002/gcc.20376
Comparative Study
Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome
Ruediger Spitz et al. Genes Chromosomes Cancer. 2006 Dec.
Abstract
The study of genomic alterations in neuroblastoma is of particular importance since several cytogenetic markers proved to be closely associated with the clinical phenotype. To disclose patterns of gains and losses, we performed high-resolution oligonucleotide array-based comparative genomic hybridization (aCGH). A total cohort of 90 patients was classified into 6 subsets according to tumor stage and outcome: Stages 1-3+ (with event), Stage 1-3- (no event), Stage 4+/-, and Stage 4S+/-. The aberration patterns in Stages 1-3- and 4S- tumors differed from all other groups as they were predominantly characterized by losses (3, 4, 14, X) and gains (7, 17) of whole chromosomes. However, 59/65 (91%) tumors of Stages 1-3+ or Stage 4 revealed numerous structural copy number alterations (sCNA). While deletions in chromosomes 1, 3, and 11 discriminated outcome in Stage 4, there were no specific sCNA that distinguished tumor stage within the subgroup of unfavorable tumors. sCNA in 1p, 3p, 11q, 17q, or MYCN amplification (MNA) was seen among 22/24 patients who died, 10/12 with metastatic relapses, and 5/9 with local recurrences. Detailed breakpoint analyses on chromosomes 1, 3, 11, and 17 disclosed preferred breaking areas, although breakpoints were not identical. Amplifications were found in 18 patients and involved 2p24 (MYCN) and other segments of chromosome 2, as well as regions on chromosome arms 6q, 12q, and 17q. One single feature in 21q21.1 (BU678720, without known function yet) attracted particular attention since five patients showed a homozygous loss of this sequence.
(c) 2006 Wiley-Liss, Inc.
Similar articles
- Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization.
Scaruffi P, Coco S, Cifuentes F, Albino D, Nair M, Defferrari R, Mazzocco K, Tonini GP. Scaruffi P, et al. Cancer Genet Cytogenet. 2007 Aug;177(1):20-9. doi: 10.1016/j.cancergencyto.2007.05.002. Cancer Genet Cytogenet. 2007. PMID: 17693187 - Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma.
Spitz R, Hero B, Ernestus K, Berthold F. Spitz R, et al. Clin Cancer Res. 2003 Oct 15;9(13):4835-40. Clin Cancer Res. 2003. PMID: 14581355 - Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
Spitz R, Hero B, Simon T, Berthold F. Spitz R, et al. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3368-73. doi: 10.1158/1078-0432.CCR-05-2495. Clin Cancer Res. 2006. PMID: 16740759 - Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q.
McArdle L, McDermott M, Purcell R, Grehan D, O'Meara A, Breatnach F, Catchpoole D, Culhane AC, Jeffery I, Gallagher WM, Stallings RL. McArdle L, et al. Carcinogenesis. 2004 Sep;25(9):1599-609. doi: 10.1093/carcin/bgh173. Epub 2004 Apr 16. Carcinogenesis. 2004. PMID: 15090470 Review. - [Analysis of genomic copy number alterations of malignant lymphomas and its application for diagnosis].
Tagawa H. Tagawa H. Gan To Kagaku Ryoho. 2007 Jul;34(7):975-82. Gan To Kagaku Ryoho. 2007. PMID: 17637530 Review. Japanese.
Cited by
- 17q Gain in Neuroblastoma: A Review of Clinical and Biological Implications.
Mlakar V, Dupanloup I, Gonzales F, Papangelopoulou D, Ansari M, Gumy-Pause F. Mlakar V, et al. Cancers (Basel). 2024 Jan 12;16(2):338. doi: 10.3390/cancers16020338. Cancers (Basel). 2024. PMID: 38254827 Free PMC article. Review. - Comparison of Next-Generation Sequencing and Fluorescence In Situ Hybridization for Detection of Segmental Chromosomal Aberrations in Neuroblastoma.
Kim E, Lee B, Lee JW, Sung KW, Kim JS. Kim E, et al. Diagnostics (Basel). 2021 Sep 17;11(9):1702. doi: 10.3390/diagnostics11091702. Diagnostics (Basel). 2021. PMID: 34574043 Free PMC article. - Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.
Cao Y, Jin Y, Yu J, Wang J, Qiu Y, Duan X, Ye Y, Cheng Y, Dong L, Feng X, Wang D, Li Z, Tian X, Wang H, Yan J, Zhao Q. Cao Y, et al. Oncotarget. 2017 Jul 25;8(30):49689-49701. doi: 10.18632/oncotarget.17917. Oncotarget. 2017. PMID: 28591696 Free PMC article. - Research progress of neuroblastoma related gene variations.
Cao Y, Jin Y, Yu J, Wang J, Yan J, Zhao Q. Cao Y, et al. Oncotarget. 2017 Mar 14;8(11):18444-18455. doi: 10.18632/oncotarget.14408. Oncotarget. 2017. PMID: 28055978 Free PMC article. Review. - Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma.
Powers JT, Tsanov KM, Pearson DS, Roels F, Spina CS, Ebright R, Seligson M, de Soysa Y, Cahan P, Theißen J, Tu HC, Han A, Kurek KC, LaPier GS, Osborne JK, Ross SJ, Cesana M, Collins JJ, Berthold F, Daley GQ. Powers JT, et al. Nature. 2016 Jul 14;535(7611):246-51. doi: 10.1038/nature18632. Epub 2016 Jul 6. Nature. 2016. PMID: 27383785 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical